tradingkey.logo
tradingkey.logo
Search

Vaximm AG Reports Phase 2A Results For VXM01 And Avelumab Combo In Glioblastoma

ReutersMar 26, 2025 11:21 AM
facebooktwitterlinkedin

- OSR Holdings Inc OSRH.O:

  • VAXIMM AG, AN OSR COMPANY, ANNOUNCES RESULTS FROM PHASE 2A TRIAL OF VXM01 AND AVELUMAB COMBINATION THERAPY IN GLIOBLASTOMA

  • VAXIMM AG - PHASE 2A TRIAL SHOWS GOOD SAFETY AND TOLERABILITY PROFILE

  • VAXIMM AG - NO SERIOUS ADVERSE EVENTS ATTRIBUTED TO VXM01

  • VAXIMM AG- DECREASED TUMOR SIZE OBSERVED IN RESPONDING PATIENTS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Tradingkey
KeyAI